HALIFAX — Nova Scotia still hasn’t signed on to the federal government’s pharmacare plan, and the province’s Opposition New ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Alnylam Pharmaceuticals's whale activity within a strike price range from $210.0 to $340 ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

The funds will facilitate the clinical progression of ABO-101, the company’s lead therapeutic candidate targeting PH1.

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...

US genetic medicines firm Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support ...

Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its ...

Jones Financial Companies Lllp bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) ...

The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating ...